Ensign Group (ENSG) is a Top-Ranked Value Stock: Should You Buy?

In this article:

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.

Why Investors Should Pay Attention to This Value Stock

Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.

Ensign Group (ENSG)

Founded in 1999 and headquartered in San Juan Capistrano, CA, The Ensign Group Inc. provides health care services in the post-acute care continuum, urgent care center and mobile ancillary businesses in the United States.

ENSG boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Ensign Group are trading at a forward earnings multiple of 18.5X, as well as a PEG Ratio of 1.2, a Price/Cash Flow ratio of 16.7X, and a Price/Sales ratio of 1.6X.

Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.10 to $4.68 per share. ENSG has an average earnings surprise of 0.6%.

ENSG should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement